行情

EVOK

EVOK

Evoke Pharma
NASDAQ

实时行情|Nasdaq Last Sale

1.430
-0.060
-4.03%
盘后: 1.530 +0.1 +6.99% 16:11 01/27 EST
开盘
1.480
昨收
1.490
最高
1.500
最低
1.420
成交量
9.58万
成交额
--
52周最高
3.260
52周最低
0.5001
市值
3,465.16万
市盈率(TTM)
-3.8462
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EVOK 新闻

  • Acceleron肺高压药物试验达到主要目标 股价暴涨79%
  • 新浪财经.1小时前
  • 英国超市巨头承诺投10亿英镑 到2040年实现零排放
  • 新浪财经.1小时前
  • 韩国政府:将全力以赴抗击疫情并稳定金融市场
  • 新浪财经.1小时前
  • 美国父母的儿童早教支出每年高达420亿美元
  • 新浪财经.2小时前

更多

所属板块

制药
-0.42%
制药与医学研究
-0.51%

热门股票

名称
价格
涨跌幅

EVOK 简况

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.
展开

Webull提供Evoke Pharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。